Intuitive Surgical (NASDAQ:ISRG – Get Free Report) had its target price hoisted by equities researchers at Leerink Partners ...

In a report released on January 16, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from Outperform to Market Perform. Analyst Price Forecast Suggests 6.67% Upside As of ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $70.37.

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Leerink Partners’ price target would indicate a potential upside of 95.50% from the stock’s current price. VIR has been the subject of several other reports. Needham & Company LLC reiterated a ...

Fintel reports that on December 12, 2024, Leerink Partners downgraded their outlook for LAVA Therapeutics N.V. (NasdaqGS:LVTX) from Outperform to Market Perform. Analyst Price Forecast Suggests ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (LSE:0HCK) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

Align Technology upgraded to Outperform with a $280 price target by Leerink Partners. Q3 adjusted EPS beats at $2.35, while sales rose 1.8% to $977.9 million. Align Technology — a medical device ...